| Literature DB >> 32120836 |
Dinesh Bharti1, Si-Jung Jang1, Sang-Yun Lee1, Sung-Lim Lee1, Gyu-Jin Rho1,2.
Abstract
In the last few decades, stem cell therapy has grown as a boon for many pathological complications including female reproductive disorders. In this review, a brief description of available strategies that are related to stem cell-based in vitro oocyte-like cell (OLC) development are given. We have tried to cover all the aspects and latest updates of the in vitro OLC developmental methodologies, marker profiling, available disease models, and in vivo efficacies, with a special focus on mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs) usage. The differentiation abilities of both the ovarian and non-ovarian stem cell sources under various induction conditions have shown different effects on morphological alterations, proliferation- and size-associated developments, hormonal secretions under gonadotropic stimulations, and their neo-oogenesis or folliculogenesis abilities after in vivo transplantations. The attainment of characters like oocyte-like morphology, size expansion, and meiosis initiation have been found to be major obstacles during in vitro oogenesis. A number of reports have either lacked in vivo studies or have shown their functional incapability to produce viable and healthy offspring. Though researchers have gained many valuable insights regarding in vitro gametogenesis, still there are many things to do to make stem cell-derived OLCs fully functional.Entities:
Keywords: differentiation; folliculogenesis; mesenchymal stem cells; oocyte-like cells; oogenesis; primordial germ cells; transfection
Mesh:
Year: 2020 PMID: 32120836 PMCID: PMC7140496 DOI: 10.3390/cells9030557
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
List of pluripotency, oocyte, germ cell, meiosis, primordial germ cell granulosa and theca cell-specific markers along with their functions. All of these markers have specific roles at various developmental stages.
| Category | Name of Gene | Function |
|---|---|---|
| Pluripotency marker | Oct4 | Regulates pluripotency and also acts as germ cell marker. |
| Nanog | Maintains pluripotency. | |
| Sox2 | Maintains pluripotency. | |
| Rex | Maintains pluripotent state. | |
| Ssea4 | Regulates the pre-implantation development and pluripotency of human embryonic stem cells. | |
| Oocyte-specific marker | Gdf9 | Oocyte maturation marker. |
| C-Mos | Oocyte maturation factor Mos. | |
| Zpc | Contributes to the structural integrity of oocyte and its coat. | |
| Stella | Involved in Chromosomal organization or RNA processing. | |
| Germ cell-specific marker | Dazl | Primordial germ cell migration, germ stem cell proliferation differentiation, Suppresses pluripotency markers expression. |
| Vasa | Germ cell determination and oocyte development. | |
| Blimp1 | Master regulator of the foundation of the germ cell lineage and primordial germ cell formation. | |
| Fragilis | Thought to be involved in the initiation of homeobox genes repression in the early germ cell precursors, and pluripotency maintenance. | |
| Meiosis-specific marker | Dmc1 | Essential for meiotic recombination and meiosis regulation. |
| Scp (1,2,3) | Synaptonemal complex protein (1,2,3) are required for normal centromere pairing, chromosomal synapsis during male and female germ cell development, important meiosis marker. | |
| Rec8 | Meiotic recombination protein which participate in meiotic process (meiotic cohesion complex, sister chromatid cohesion and homologous chromosome recombination). | |
| Stra8 | Regulation of meiotic initiation in both spermatogenesis and oogenesis. | |
| Primordial germ cell marker | Prdm1/Blimp-1 | Repress beta-interferon gene expression, plays critical role in primordial germ cells and germ cell formation. |
| Prdm14 | Maintain pluripotency and suppress the expression of differentiation marker genes, helps in primordial germ cell formation. | |
| Dppa3 | Developmental pluripotency-associated protein 3 participate in epigenetic chromatin reprogramming, prevent 5mC to conversion (DNA methylation protection), the condensation of chromatin during oocytogenesis. | |
| Dnd1 | Survival of primordial germ cells, germ cell tumor suppression in mice, apoptosis suppression. | |
| Nanos3 | Maintain undifferentiated germ cell state, participate in human germ cell development, apoptosis suppression. | |
| Tcfap2c/Ap2-γ | Placenta development, primordial germ cell maintenance. | |
| Granulosa cell marker | Foxl2 | Important for ovarian development and function, granulosa cell differentiation marker, support pre-ovulatory follicles growth. |
| Amh | TGF-β family member, help in the proliferation of mitotically active germ cell, folliculogenesis regulation, molecule biomarker for ovarian reserve and menopause timing. | |
| FshR | Expressed by granulosa cell, necessary follicular development, controls the growth and maturation of spermatogenesis and follicle formation. | |
| CYP19A1 | Helps in estrogen biosynthesis. | |
| Theca cell marker | LHR | Helps in follicular maturation, ovulation and luteal function. |
Detailed description of different species-derived, oocyte-like cells (OLCs) and primordial germ cells (PGCs) when using co-culture and follicular fluid.
| Stem Cell Source | Co-Culture | FF Concentration | Final Product | Reference | |
|---|---|---|---|---|---|
| Human | Ovarian stem cell | MEF layer | 0 | OLCs | [ |
| Wharton’s jelly | Placental cells | 0 | OLCs | [ | |
| Theca cell | GCs | 5% human | OLCs | [ | |
| Menstrual blood-derived endometrial MSC | GCs | 0 | OLCs | [ | |
| Induced Pluripotent Stem Cells | Fetal gonadal stromal cells | 0 | PGCs | [ | |
| Embryonic stem cell | Fetal gonadal stromal cells | 0 | PGCs | [ | |
| Embryonic stem cell | MEF layer | 0 | PGCs | [ | |
| Porcine | Female germline stem cell | GCs | 5% porcine | OLCs | [ |
| Female germline stem cell | MEF layer | 5% porcine | OLCs | [ | |
| Mouse | Skin-derived stem cell | MEF layer | 0 | PGCs | [ |
| Skin-derived stem cell | MEF layer | 0 | PGCs | [ | |
| Skin-derived stem cell | Newborn mouse ovarian cells | 0 | OLCs | [ | |
| Embryonic stem cell | Ovarian somatic cells | 0 | OLCs | [ | |
| Embryonic stem cell | GCs | 0 | OLCs | [ | |
| Embryonic stem cell | GCs | 0 | Germ-like cells | [ | |
| Embryonic stem cell | New born mouse granulosa cells | 0 | OLCs | [ | |
| Embryonic stem cell | OP9 stromal cells | 0 | PGC-like cells | [ | |
| Ovarian stem cell | GCs | 0 | OLCs | [ | |
| Female germline stem cell | GCs | 0 | OLCs | [ | |
| Embryonic stem cell | MEF layer | 0 | PGCs | [ | |
MEF: mouse embryonic fibroblast; GCs: granulosa cells; OLCs: oocyte-like cells; and PGCs: primordial germ cells.
List of transfection-based female germ-specific studies, along with their description including cell source used and final research outputs.
| Cell Source | Transfection | Final Product | Implication | Knockdown | Reference | |
|---|---|---|---|---|---|---|
| Human | ASCs | BMP15 | OLCs | BMP15 activation, expressed oocyte-specific markers (ZP1, ZP2, ZP3, c-kit), detection of VASA protein during later stage of induction. | x | [ |
| ESCs | NANOS3 | Germ cells | Over expressed protein levels PRKSCH. No expression of OLFM2, delayed in vitro differentiation. | x | [ | |
| ESCs | DAZL | Germ cells | Up-regulated DAZL, IFITM3, BMP7, HIP1R, ISYNA1, JAG2, PIDD1, RPRM. Down-regulated CXCL5, GABRP, FAM110C, LCP1. | x | [ | |
| ESCs | DAZL, BOULE | Follicle-like cells | Increased DAZL and BOULE expression. | shRNA (DAZL) | [ | |
| ASCs | BMP15 | OLCs, GC | Differentiation into OLC, GC, with increased size, BMP15 activation and parthenogenetic embryo-like structures formation. | x | [ | |
| UCMSCs | FIGLα | OLCs | Over expressed Figlα, | x | [ | |
| ESCs | PRDM1 | PGCs | Suppressed Sox2 expression, | shRNA (PRDM1) | [ | |
| Mouse | ESCs | FIGLα | Female germ-like cells | Differentiation into germ-like cells, high expression of germ cell markers (VASA), meiotic-specific genes (STRA8, SCP3), and oocyte markers (GDF9, ZP3, FIGLα). | x | [ |
| ESCs | DAZL | Germ cells | Overexpression of DAZL. | siRNA (DAZL) | [ | |
| ESCs | PRDM1 | Germ cells | Suppressed SOX2 expression and neural fate, increased expression of markers like PRDM1, OCT4, NANOS3, VASA and SCP3, enhances BMP4 & WNT3A induced germline differentiation. | x | [ | |
| Embryonal carcinoma cells | BLIMP1, PRDM14, AP2γ | PGCs | Directed EpiLCs formation, | x | [ | |
| Porcine | Ovarian cortex | OCT4 | OLCs | Oct4 overexpression. | x | [ |
| Skin-derived stem cells | DAZL | PGCs | Induced differentiation. | siRNA (DAZL) | [ | |
| Goat | Ear Pinnae cells | OCT4, SOX2, NANOG | iPSCs OLCs | Cell reprogramming, increased potency. | x | [ |
ASCs: amniotic fluid stem cells; ESCs: embryonic stem cells; UCMSCs: umbilical cord mesenchymal stem cells; OLCs: oocyte-like cells; PGCs: primordial germ cells; PRKSCH: protein kinase C substrate 80K-H; OLFM2: Olfactomedin2; IFITM3: interferon-induced transmembrane protein; BMP7: bone morphogenetic protein 7; HIP1R: huntingtin interacting protein 1 related; ISYNA1: inositol-3-phosphate synthase 1; JAG2: jagged 2; PIDD1: p53-induced death domain protein 1; RPRM: reprimo; CXCL5: chemokine ligand 5; GABRP: gamma-aminobutyric acid a receptor, Pi; FAM110C: family with sequence similarity 110, Member C; and LCP1: lymphocyte cytosolic protein 1.
Figure 1Schematic presentation of stem cell-derived oocyte-like cells when using various strategies and their in vivo efficacies. This figure demonstrates that stem cells (embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs)) can be obtained from various organs of different organisms. These cells, upon treatment with specific cytokines, growth factors or differentiation inducers, can be used to differentiate oocyte-like cells (OLCs). These differentiated cells can be further transplanted to disease models to cure the disease.
Figure 2Stem cell utilization for restoration of reproductive properties in diseased animal models. This figure demonstrates that stem cells can be directly injected to cure the diseased animals either by stem cells induced paracrine signaling or by secreted microRNA (miRNAs)/very small embryonic-like stem cells (VSELs).
In vivo efficacy of mesenchymal stem cells regarding the treatment of female reproductive disorders.
| Stem Cell Source | Target Disease Model | Implication | Reference | |
|---|---|---|---|---|
| Bone marrow mesenchymal stem cell | Mouse | POF | Formed primordial follicles, increased E2 level, decreased FSH level, attained pregnant after natural breeding. | [ |
| Rabbit | POF | Increased E2 and VEGF levels, decrease FSH level, increased follicle number. | [ | |
| Human | POF | After transplantation menstruation improved, one case delivered healthy full baby, increased ovarian reserve score. | [ | |
| Umbilical cord mesenchymal stem cell | Human | POF | Decreased serum FSH level, recovery in serum E2 and AMH levels, increase in secondary follicles, reduced ovarian cell’s apoptosis. | [ |
| Human | POI | Increased body weight, estrous cycle recovery, increase in ovarian follicles, increase in serum E2 level, decrease in serum FSH level, induced angiogenesis and cytokine expression in the ovary. | [ | |
| Human | POI | Increase in ovarian weight, increased weight in E2-dependent organs, increased follicular number, decrease in serum FSH level, increase in AMH level, increased AMH expression, elevation in pregnancy rate. | [ | |
| Menstrual blood stem cell | Human | POF | Increased expression of ovarian markers [AMH, inhibin α/β, and follicle-stimulating hormone receptor (FSHR)], increased Ki67 expression, increased ovarian weight, increased plasma E2 level and increased number of normal follicles. | [ |
| Human | POI | Increased ovarian weight and total follicle number, estrus cycle restoration, decreased serum FSH level, increased serum E2, AMH level, reduced apoptosis, increase in the expression of AMH, DDX4 and VEGFA. | [ | |
| Amniotic MSC | Human | Natural ovarian aging | Increase in all stage follicle number, recovery in E2 and AMH levels, decreased FSH levels, promoted the proliferation rate, high expression of ovarian and granular cell markers (AMH, FSHR, FOXL2, CYP19A1). | [ |
| Human | POF | Recovered estrus cycle, increase in estrogen level, decrease in FSH levels, increase in ovarian index, fertility rate and population of follicles at different stages. | [ | |
| Chorionic MSC | Human | POF | Decreased serum FSH level, increased serum E2 level and number of follicles, restored estrous cycle, increased oocyte population. | [ |
| Adipose-derived MSC | Human | Damaged ovarian | Induced angiogenesis, increase in ovarian follicles, corpus luteal and also in number of litters. | [ |
| Endometrial MSC | Human | POF | Increased body weight, restored estrus cycle, re- established fertility, MSC infiltration to damaged ovarian tissue and differentiated into granulosa cell, improved renewal of germline stem cells. | [ |
| Skin-derived MSC | Mouse | POF | Increased body weight, increased weight of reproductive organs, restored fertility, reduced pro-inflammatory cytokines (TNF-a, TGF-b, IL-8, IL-6, IL-1b, and IFN γ), increased expression of genes Nobox, Nanos3, and Lhx8 genes in the transplanted ovaries. | [ |
POF: premature ovarian failure; POI: premature ovarian insufficiency; FSH: follicular stimulating hormone; LH: luteinizing hormone; AMH: anti Mullerian hormone; and E2: estradiol.
Description about the list of ongoing clinical trials that are associated with the use of stem cells in curing female reproductive disorders. All of these details were taken from https://stemcellsportal.com/clinical_trials_infertility.
| Pathological Condition | Cell Therapy | Estimated Enrollment | Intervention/ | Cliniclatrials.Gov Identifier | Outcome Measures |
|---|---|---|---|---|---|
| Women infertility with thin endometrium or endometrial scarring. | UCMSCs loaded in collagen scaffold | 50 participants | UCMSC-based therapy | NCT03592849 | Evaluation of endometrial thickness, pregnancy rate, living intrauterine fetus, live birth rate, endometrial blood flow, menstrual blood volume and adversities such as infection, allergies, abdominal pain post-operation. |
| Women with POI | AECs | 20 participants | Minimally invasive implantation AECs used with ultrasound guidance | NCT03207412 | Evaluation of serum FSH, primordial egg follicles number, menstrual cycle and menstrual period, LH, AMH and E2, ovarian volume. |
| Repeated IVF failure women with atrophic endometrium | Autologous BMSCs | 46 participants | Transplantation of BMSCs | NCT03166189 | Evaluation of endometrial receptivity, endometrial thickness, pregnancy rate, adversities such as side effects, abdominal discomfort and patient’s tolerance. |
| Women with POF | Autologous BMSCs | 33 participants | Transplantation of BMSCs | NCT02696889 | Evaluation of FSH, AMH, E2 level, menstruation resumption, pregnancy achievement. |
| Women with POF | Autologous AMSCs | 9 participants | Intra-ovarian injection of AMSCs | NCT02603744 | Evaluation of FSH, AMH, antral follicle number and volume, menstruation recurrence rate and pregnancy rate. |
| Women infertility with intrauterine adhesions | UCMSCs loaded in collagen scaffold | 26 participants | UCMSC-based therapy | NCT02313415 | Evaluation of live birth rate, intrauterine adhesion reduction, change of endometrial thickness, menstrual blood volume. |
| Women infertility with intrauterine adhesions and endometrial dysplasia | Autologous BMSCs loaded in collagen scaffold | 30 participants | BMSC-based therapy | NCT02204358 | Evaluation of intrauterine scar reduction, endometrial thickness, menstrual blood volume and pregnancy rate. |
| Women with POF | Autologous BMSCs | 60 participants | Transplantation of BMSCs | NCT02062931 | Evaluation of FSH, AMH, E2 level, hormonal, clinical, ultra sound, menopausal symptoms and pregnancy rate. |
UCMSCs: umbilical cord mesenchymal stem cells; AECs: amniotic epithelial cells; BMSCs: bone marrow-derived mesenchymal stem cells; AMSCs: adipose mesenchymal stem cells; POF: pre-mature ovarian failure; POI: pre-mature ovarian insufficiency; FSH: follicular stimulating hormone; LH: luteinizing hormone; AMH: anti Mullerian hormone; and E2: estradiol.